R. Cooper

International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.

G. Serratrice, D. Isenberg, J. Callen, 2004, Rheumatology.

IMPLICATIONS OF ANTI-CN1A SEROTYPE IN INCLUSION BODY MYOSITIS

J. Lamb, B. V. van Engelen, S. Pye, 2016, Journal of Neurology, Neurosurgery & Psychiatry.

Proceedings of the 13th International Newborn Brain Conference: Neuro-imaging studies.

A. Leemans, D. Ferriero, C. Slump, 2022, Journal of neonatal-perinatal medicine.

Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies.

D. Isenberg, V. Farewell, J. Vencovský, 2001, Rheumatology.

Selected aspects of the current management of myositis

J. Lilleker, S. Murphy, R. Cooper, 2016, Therapeutic advances in musculoskeletal disease.

Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.

D. Stram, K. Matthay, R. Gerbing, 2001, Medical and pediatric oncology.